Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

743
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
743
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

35
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
35
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

922
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
922
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper and lower respiratory airway complaints among female veterinary staff.

International archives of occupational and environmental health·2021
Same author

Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis.

Pulmonology·2021
Same author

Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals.

Pneumologie (Stuttgart, Germany)·2021
Same author

Systematic rifampicin resistance errors with Xpert<sup>®</sup> MTB/RIF Ultra: implications for regulation of genotypic assays.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Cost of multidrug resistant tuberculosis in Germany-An update.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2020
Same author

Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in general and pneumologist practices in Germany.

Journal of clinical tuberculosis and other mycobacterial diseases·2020

Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.9K

[Current Issues Arising from Tuberculosis Screening with Interferon-Gamma-Release Assays (IGRAs)].

R Diel1, A Nienhaus2

  • 1Institut für Epidemiologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel.

Pneumologie (Stuttgart, Germany)
|May 14, 2015
PubMed
Summary

Interferon-gamma release assays (IGRAs) may show variable results in healthcare workers. Positive IGRA tests require careful interpretation considering latent tuberculosis infection (LTBI) prevalence and individual risk factors for accurate diagnosis.

More Related Videos

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

6.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 12, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.9K
Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

6.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Interferon-gamma release assays (IGRAs) are widely used for tuberculosis (TB) diagnosis.
  • Interpreting IGRA results requires careful consideration of latent tuberculosis infection (LTBI) prevalence.
  • Variability in IGRA results, including conversions and reversions, can occur with repeated testing, particularly in healthcare workers.

Purpose of the Study:

  • To evaluate the interpretation of IGRA results in the context of LTBI prevalence.
  • To assess the significance of IGRA test variability in healthcare workers undergoing serial testing.
  • To determine the predictive value of positive IGRA results for progression to active TB disease.

Main Methods:

  • Review of current scientific knowledge on IGRA performance and interpretation.
  • Analysis of IGRA test results in populations with varying LTBI prevalence.
  • Consideration of serial IGRA testing in healthcare worker cohorts.

Main Results:

  • Positive IGRA results do not definitively confirm LTBI; prevalence is a critical factor in interpretation.
  • Repeated IGRA testing in healthcare workers can lead to result variabilities (conversions/reversions).
  • Positive IGRA results alone do not reliably predict progression to active TB disease.

Conclusions:

  • IGRA interpretation must account for LTBI prevalence and individual risk assessment.
  • Testing should be reserved for individuals with established risk factors for Mycobacterium tuberculosis (M.tb.) infection.
  • Current evidence suggests IGRAs are not superior to the tuberculin skin test (TST) in young children.